Votrient for Soft Tissue Sarcoma

Details

Files
Generic Name:
Pazopanib Hydrochloride
Project Status:
Complete
Therapeutic Area:
Soft Tissue Sarcoma
Manufacturer:
GlaxoSmithKline Inc.
Brand Name:
Votrient
Project Line:
Reimbursement Review
Project Number:
PC0009-000
Strength:
200 mg
Tumour Type:
Sarcoma
Indications:
Soft Tissue Sarcoma (STS)
Funding Request:
Adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Funding is not requested for patients with GIST and adipocytic soft tissue sarcomas.
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
GlaxoSmithKline Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.